Literature DB >> 28573460

Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats.

Emanuel Candeias1,2, Inês Sebastião1, Susana Cardoso1,2, Cristina Carvalho1,2, Maria Sancha Santos1,3, Catarina Resende Oliveira1,4, Paula I Moreira5,6, Ana I Duarte7,8.   

Abstract

Type 2 diabetes (T2D) is a modern socioeconomic burden, mostly due to its long-term complications affecting nearly all tissues. One of them is the brain, whose dysfunctional intracellular quality control mechanisms (namely autophagy) may upregulate apoptosis, leading to cognitive dysfunction and Alzheimer disease (AD). Since impaired brain insulin signaling may constitute the crosslink between T2D and AD, its restoration may be potentially therapeutic herein. Accordingly, the insulinotropic anti-T2D drugs from glucagon-like peptide-1 (GLP-1) mimetics, namely, exendin-4 (Ex-4), could be a promising therapy. In line with this, we hypothesized that peripherally administered Ex-4 rescues brain intracellular signaling pathways, promoting autophagy and ultimately protecting against chronic T2D-induced apoptosis. Thus, we aimed to explore the effects of chronic, continuous, subcutaneous (s.c.) exposure to Ex-4 in brain cortical GLP-1/insulin/insulin-like growth factor-1 (IGF-1) signaling, and in autophagic and cell death mechanisms in middle-aged (8 months old), male T2D Goto-Kakizaki (GK) rats. We used brain cortical homogenates obtained from middle-aged (8 months old) male Wistar (control) and T2D GK rats. Ex-4 was continuously administered for 28 days, via s.c. implanted micro-osmotic pumps (5 μg/kg/day; infusion rate 2.5 μL/h). Peripheral characterization of the animal models was given by the standard biochemical analyses of blood or plasma, the intraperitoneal glucose tolerance test, and the heart rate. GLP-1, insulin, and IGF-1, their downstream signaling and autophagic markers were evaluated by specific ELISA kits and Western blotting. Caspase-like activities and other apoptotic markers were given by colorimetric methods and Western blotting. Chronic Ex-4 treatment attenuated peripheral features of T2D in GK rats, including hyperglycemia and insulin resistance. Furthermore, s.c. Ex-4 enhanced their brain cortical GLP-1 and IGF-1 levels, and subsequent signaling pathways. Specifically, Ex-4 stimulated protein kinase A (PKA) and phosphoinositide 3-kinase (PI3K)/Akt signaling, increasing cGMP and AMPK levels, and decreasing GSK3β and JNK activation in T2D rat brains. Moreover, Ex-4 regulated several markers for autophagy in GK rat brains (as mTOR, PI3K class III, LC3 II, Atg7, p62, LAMP-1, and Parkin), ultimately protecting against apoptosis (by decreasing several caspase-like activities and mitochondrial cytochrome c, and increasing Bcl2 levels upon T2D). Altogether, this study demonstrates that peripheral Ex-4 administration may constitute a promising therapy against the chronic complications of T2D affecting the brain.

Entities:  

Keywords:  Apoptosis; Autophagy; Brain cortex; Exendin-4; GLP-1 signaling; Type 2 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28573460     DOI: 10.1007/s12035-017-0622-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  22 in total

Review 1.  The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.

Authors:  Niklas Reich; Christian Hölscher
Journal:  Front Neurosci       Date:  2022-09-01       Impact factor: 5.152

2.  Activation of IGF-1/GLP-1 Signalling via 4-Hydroxyisoleucine Prevents Motor Neuron Impairments in Experimental ALS-Rats Exposed to Methylmercury-Induced Neurotoxicity.

Authors:  Ambika Shandilya; Sidharth Mehan; Sumit Kumar; Pranshul Sethi; Acharan S Narula; Abdulrahman Alshammari; Metab Alharbi; Abdullah F Alasmari
Journal:  Molecules       Date:  2022-06-16       Impact factor: 4.927

Review 3.  The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain.

Authors:  Choon Sang Bae; Juhyun Song
Journal:  Int J Mol Sci       Date:  2017-11-22       Impact factor: 5.923

Review 4.  Sweet Mitochondria: A Shortcut to Alzheimer's Disease.

Authors:  Paula I Moreira
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  Exendin-4 and Liraglutide Attenuate Glucose Toxicity-Induced Cardiac Injury through mTOR/ULK1-Dependent Autophagy.

Authors:  Wei Yu; Wenliang Zha; Jun Ren
Journal:  Oxid Med Cell Longev       Date:  2018-04-19       Impact factor: 6.543

Review 6.  Apoptosis in Autoimmunological Diseases, with Particular Consideration of Molecular Aspects of Psoriasis.

Authors:  Agata Krawczyk; Joanna Miśkiewicz; Karolina Strzelec; Dominika Wcisło-Dziadecka; Barbara Strzalka-Mrozik
Journal:  Med Sci Monit       Date:  2020-06-22

7.  Yu Nu Compound Regulates Autophagy and Apoptosis Through mTOR in vivo and vitro.

Authors:  Caigu He; Guang Liu; Shuting Zhuang; Jialin Zhang; Yangtao Chen; Hetian Li; Zhengping Huang; Yanfang Zheng
Journal:  Diabetes Metab Syndr Obes       Date:  2020-06-18       Impact factor: 3.168

8.  High glucose exacerbates neuroinflammation and apoptosis at the intermediate stage after post-traumatic brain injury.

Authors:  Wenqian Zhang; Jun Hong; Wencheng Zheng; Aijun Liu; Ying Yang
Journal:  Aging (Albany NY)       Date:  2021-06-27       Impact factor: 5.682

9.  GLP-1-Induced AMPK Activation Inhibits PARP-1 and Promotes LXR-Mediated ABCA1 Expression to Protect Pancreatic β-Cells Against Cholesterol-Induced Toxicity Through Cholesterol Efflux.

Authors:  Rao Li; Xulong Sun; Pengzhou Li; Weizheng Li; Lei Zhao; Liyong Zhu; Shaihong Zhu
Journal:  Front Cell Dev Biol       Date:  2021-07-07

10.  Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin.

Authors:  Grazyna Lietzau; William Davidsson; Claes-Göran Östenson; Fausto Chiazza; David Nathanson; Hiranya Pintana; Josefin Skogsberg; Thomas Klein; Thomas Nyström; Vladimer Darsalia; Cesare Patrone
Journal:  Acta Neuropathol Commun       Date:  2018-02-23       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.